Literature DB >> 25159217

IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants.

Charani Ranasinghe1, Shubhanshi Trivedi2, Danushka K Wijesundara3, Ronald J Jackson2.   

Abstract

The roles of interleukin (IL)-4 and IL-13 during both innate and adaptive Th2 mediated immunity have received considerable scrutiny, however, mechanisms by which these cytokines influence the cellular interactions involved in negatively modulating the development of effective Th1 immunity are poorly characterized. In this article we discuss the recent advances in IL-4/IL-13 biology, mainly (i) role of these cytokines in allergic inflammation, atopic dermatitis, cancer, transplant rejection, bacterial/viral infections, and specifically the therapeutic potential of IL-13Rα2, (ii) insights into how "alarmin" stimulation activate IL-4/IL-13 at the lung mucosae, (iii) how these two cytokines modulate antigen-specific CD8(+) T cell quality/avidity in a vaccine route dependent manner and (iv) finally discuss the potential of using transient inhibition of IL-4 and/or IL-13 at the vaccination site as a platform vaccine technology to induce strong sustained high quality CD8(+) T cell immunity for protection against many chronic mucosal pathogens such as HIV-1.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  CD8 T cell avidity; IL-13Ra2; IL-4R antagonist; Infection and immunity; Vaccines

Mesh:

Substances:

Year:  2014        PMID: 25159217     DOI: 10.1016/j.cytogfr.2014.07.010

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  25 in total

1.  Single-cell sequencing of rotavirus-infected intestinal epithelium reveals cell-type specific epithelial repair and tuft cell infection.

Authors:  Carolyn Bomidi; Matthew Robertson; Cristian Coarfa; Mary K Estes; Sarah E Blutt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

2.  The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.

Authors:  Clare M Williams; Sreeja Roy; Danielle Califano; Andrew N J McKenzie; Dennis W Metzger; Yoichi Furuya
Journal:  J Virol       Date:  2021-09-01       Impact factor: 5.103

Review 3.  The IL-13-OVOL1-FLG axis in atopic dermatitis.

Authors:  Kazuhisa Furue; Takamichi Ito; Gaku Tsuji; Dugarmaa Ulzii; Yen Hai Vu; Makiko Kido-Nakahara; Takeshi Nakahara; Masutaka Furue
Journal:  Immunology       Date:  2019-10-01       Impact factor: 7.397

4.  STAT3 determines IL-4 signalling outcomes in naïve T cells.

Authors:  Lachlan P Deimel; Zheyi Li; Sreeja Roy; Charani Ranasinghe
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

5.  Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?

Authors:  Reinhart Speeckaert; Jo Lambert; Luis Puig; Marijn Speeckaert; Hilde Lapeere; Sofie De Schepper; Nanja van Geel
Journal:  Drugs R D       Date:  2021-06-09

6.  Vaccination route can significantly alter the innate lymphoid cell subsets: a feedback between IL-13 and IFN-γ.

Authors:  Zheyi Li; Ronald J Jackson; Charani Ranasinghe
Journal:  NPJ Vaccines       Date:  2018-03-12       Impact factor: 7.344

7.  Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.

Authors:  Anette Holck Draborg; Noreen Sandhu; Nanna Larsen; Janni Lisander Larsen; Søren Jacobsen; Gunnar Houen
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

8.  Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.

Authors:  Megan Laudenbach; Federico Baruffaldi; Christine Robinson; Philipp Carter; Davis Seelig; Carly Baehr; Marco Pravetoni
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

Review 9.  Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Authors:  Martin Braddock; Nicola A Hanania; Amir Sharafkhaneh; Gene Colice; Mats Carlsson
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

Review 10.  Emerging Targets for Developing T Cell-Mediated Vaccines for Human Immunodeficiency Virus (HIV)-1.

Authors:  Danushka K Wijesundara; Charani Ranasinghe; Branka Grubor-Bauk; Eric J Gowans
Journal:  Front Microbiol       Date:  2017-10-25       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.